Durvalumab (D) +/- tremelimumab (T) plus platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study
Date
2022Author
Xie, Mingchao
Chen, Yuanbin
Hotta, Katsuyuki
Poltoratskiy, Artem
Hochmair, Maximilian J.
ÖZGÜROĞLU, Mustafa
Ji, Jun Ho
Statsenko, Galina
Voitko, Oleksandr
Conev, Nikolay V.
Bondarenko, Igor
Mann, Helen
Bischoff, Helge
Paz-Ares, Luis
Dalvi, Tapashi
Chugh, Priti
Shrestha, Yashaswi
Goldman, Jonathan W.
Garassino, Marina Chiara
Metadata
Show full item recordCollections
- Makale [92796]